Institut National de la Sant? et de la Recherche M?dicale provides medical services. The firm specializes in biomedical research and public health research. The company is headquartered in Paris, Cedex, France.

Servier are driven by the belief in the excellence of their profession. Theirs is a research-based organization, fulfilling a basic need and dedicated to the future.

Novartis Vaccines & Diagnostics, Inc. manufactures and markets health care and nutritional products. The company was founded in 1986 and is headquartered in East Hanover, NJ.

Pharmacia Corp. developed, manufactured and marketed pharmaceutical products. Prescription pharmaceuticals included general therapeutics, ophthalmology and hospital products including oncology and diversified therapeutics. It also operated in consumer health care, animal health, diagnostics and contract manufacturing and bulk pharmaceutical chemicals. The customers of the group were pharmacies, hospitals, chain warehouses, governments, physicians, wholesalers and other distributors. It was headquartered in Peapack, NJ.

Universal Diagnostics S.L. (UDX) is a Spanish in-vitro diagnostics company developing a platform of minimally-invasive, blood-based solutions for detecting cancer early when treatment options are more plentiful and survival rates are still high. UDX believes that the best way to fight against cancer is by detecting it early. The UDX diagnostic platform is designed to detect various cancer types, e.g. colorectal, liver, pancreatic, lung, and gastric cancer via one simple blood test. The assays rely on a curated set of proprietary methylation marker panels; a simple blood sample collected as part of a routine check-up, can be processed at a reference laboratory or hospital using standard equipment and then uploaded to the UDX Cloud for final algorithmic analysis. UDX’s first marker panel is a colorectal cancer screening test. The test identifies individuals who need to be referred for colonoscopy. Colorectal cancer is the 3rd most frequent cancer and 2nd deadliest cancer worldwide. The challenge is that colorectal cancer is mostly detected in late stages, with significantly decreased survival rates (11% survival rate in stage IV vs. 85% survival rate in stage I). To develop the test and execute its R&D and operations, UDX partners with international research institutions, hospitals, universities, and biobanks around the globe.

VastCon Inc. is a biotech company developing early screening and diagnostics for cancer. VastCon was founded in 2011 by Drs. Anuraag Shrivastav and Shailly Varma Shrivastav and is headquartered in Winnipeg, Manitoba, Canada. The company includes a team of basic research scientists with the mandate to take research from the laboratory to bedside. VastCon’s lead product is a novel blood test for the early detection and screening of colorectal cancer. Colorectal cancer is the second or third leading cause of death due to cancer world-wide, despite being one of the most curable cancers if detected early. Unfortunately for many people, by the time it is detected it is already at an advanced stage leading to death.

Epitech Group is a biological pharmacology company founded in 2001 by experts in the sector who, starting from significant experience, have dedicated their activities to the identification, study and validation of new pharmacological modulation mechanisms applied to the development, production and marketing of advanced systems and innovative therapy with different types of applications.

Manufactures and distributes cancer treatment products and therapeutics

Mor Research Applications is the Technology Transfer Office of Clalit Health Services, the largest HMO in Israel, providing end-to-end technology transfer services. MOR helps inventors translate new ideas in the medical, pharmaceutical, diagnostics, medical IT, and biotechnology areas into products and solutions that benefit healthcare providers and patients.

Chiron Corporation (/ˈkaɪrɒn/ KY-ron) was an American multinational biotechnology firm based in Emeryville, California that was acquired by Novartis on April 20, 2006. It had offices and facilities in eighteen countries on five continents. Chiron's business and research was in three main areas: biopharmaceuticals, vaccines, and blood testing. Chiron's vaccines and blood testing units were combined to form Novartis Vaccines and Diagnostics, while Chiron BioPharmaceuticals was integrated into Novartis Pharmaceuticals. In 2014, Novartis completed the sale of its blood transfusion diagnostics unit to Grifols and announced agreements for the sale of its vaccines unit to GlaxoSmithKline.

Tianjin Yujin Artificial Intelligence Medical Technology Co., Ltd., established on 2018-10-17, Business scope includes licensed projects:Production of Class II Medical Devices;Production of Class III Medical Devices;Class III medical device business;The second type of value-added telecommunications services.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments,The specific business items are subject to the approval documents or licenses of relevant departments)General project:AI Hardware Sales;software development;Sales of Class I Medical Devices;Sales of Class II Medical Devices;Class II Medical Device Leasing;Class III Medical Device Leasing;Business Management Consulting;Health Consulting Services(Does not include medical services);Artificial intelligence application software development;Artificial intelligence public service platform technical consulting services;Artificial intelligence theory and algorithm software development;Artificial intelligence public data platform;Artificial intelligence basic software development;Artificial intelligence basic resources and technology platform;Artificial intelligence industry application system integration service;Artificial intelligence innovation and innovation service platform;Artificial intelligence general application system;internet sales(Except for products that require a license for sale);Information system integration service;internet data service;Production of protective equipment for medical personnel(Ι class medical device);Wholesale of protective equipment for medical staff;Information Consulting Service(Not including licensing information consulting services);Information Technology Consulting Services;Technical Services,technology development,technical consulting,Technology Exchange,technology transfer,Technology Promotion;Cloud Computing Equipment Technical Services;5GCommunication Technology Services;Office Supplies Sales;Wholesale of computer software, hardware and auxiliary equipment;Computer and communication equipment rental;Retailing of computer software, hardware and auxiliary equipment;Computer System Services;Manufacturing of computer software, hardware and peripheral equipment;software sales;Information security equipment sales;Sales of commercial encryption products;Internet equipment sales;Digital Video Surveillance System Sales;Educational Consulting Services(Education and training activities that do not include licensing approval);Integrated circuit chips and product sales;Integrated circuit chip design and service;Integrated circuit chip and product manufacturing;Manufacturing of other electronic devices;Production of commercial encryption products;IC sales;Sales of power electronic components;integrated circuit manufacturing;Wholesale of electronic components;Manufacturing of electronic components;Manufacturing of Power Electronic Components;Electrical instrumentation manufacturing;IC Design;Sales of office equipment consumables;Electronic Components Retail.(Except for projects subject to approval by law,Carry out business activities independently in accordance with the law with a business license)(Not allowed to invest<Negative List for Foreign Investment Access>Fields where foreign investment is prohibited)

The Board of Regents of The University of Texas System, a subsidiary of The University of Texas at Austin, is an American company located in Austin, TX. The firm oversees college activities.

Oncotherapy science (OTS) is“ to deliver cancer therapeutics and treatments with higher efficacy and fewer side effects to patients suffering from cancer as soon as possible, and to overcome the fight against cancer. Was established with the aim of OTS brought Professor Genomix (Science that handles genetic information systematically) as a pioneer in the medical field with Prof. Atsushi Nakamura (Director, Cancer Precision Medical Research Center, Institute of Cancer, Professor Emeritus, The University of Tokyo, Professor Emeritus of Chicago University) Joint research to identify target molecules suitable for cancer drug development based on comprehensive gene expression analysis, and promote research and development of small molecule drugs, cancer peptide vaccines and antibody drugs for those targets.

Metabolomic Technologies Inc. (MTI) is a spin-off company from the University of Alberta. The company was formed from a research program facilitated by Drs. Haili Wang and Richard Fedorak, who were interested in using the new science of metabolomics to explore how colorectal cancer and adenomatous (precancerous) polyps affected cellular metabolism. At MTI, they are committed to developing advanced metabolomic-based diagnostic tests for the management of chronic diseases or ‘high value’ diagnostics. Their initial focus is on developing highly novel, patented, metabolomic-based, diagnostic tests to detect adenomatous polyps and colorectal cancer (CRC). CRC is a leading cause of death in North America, but is curable if identified through early screening processes. However, current fecal-based screening methodologies are suboptimal due to a lack of sensitivity and acceptability. Their flagship product, PolypDx™, a spot urine diagnostic test, innovatively offers a significantly higher sensitivity in detecting adenomatous polyps and thus significantly advances the prevention of CRC.

American Cyanamid Company was a U.S.-based diversified company with businesses in several fields. The company was a manufacturer of agricultural chemicals, cosmetics, perfumes, building products, plastics and pharmaceuticals. The company was listed as a top 100 manufacturing company by Fortune magazine in the 1970s. Cyanamid was founded in 1907 and employed over 100,000 people around the world by 2000. The company maintained a monopoly over tetracycline, an antibiotic used against bacterial infections. A theft of the organism led to the loss of the monopoly as rival companies were able to produce generic versions of the formula, leading to huge losses to the company. The company sold most of its businesses in the early 2000s and is now operated under the name Cytec.  

Massachusetts General Hospital was established to provide care to Boston's sick, regardless of socioeconomic status—an innovative idea in 1811. In the words of their founder, John Warren, MD, “When in distress, every man becomes their neighbor.” They subsequently became the first teaching hospital for Harvard University’s new medical school and have been redefining excellence in healthcare ever since. They have remained at the forefront of medicine by fostering a culture of collaboration, pushing the boundaries of medical research, educating the brightest medical minds and maintaining an unwavering commitment to the diverse community they were created to serve. They believe that because of diversity they excel, through inclusion they respect their community, and with a keen focus on equity they serve, heal, educate and innovate at the highest levels. Their first priority is the well-being of their patients—near and far. As a team they are able to maintain a singular focus on providing the highest quality, most compassionate care to each and every patient.

G.D. Searle, LLC is a wholly owned trademark of Pfizer. It is currently used mainly as a distribution trademark for various pharmaceuticals that were developed by G. D. Searle & Company (often referred to as Searle). Prior to its 1985 merger with Monsanto, Searle was a company focusing on life sciences, specifically pharmaceuticals, agriculture, and animal health.